-
S.Africa anti-migrant hate loses team African support at World Cup
-
Arsenal will start Premier League title defence against Coventry
-
European robotics start-ups go up against Chinese heavyweights
-
'Alter-Ego': An Italian hospital's little robot carer
-
Japan's men told to clean at home, not just the World Cup
-
French court confirms Moroccan football star Hakimi will stand trial for rape
-
South Korean leader says told Trump sanctions on North are 'ineffective'
-
Deadly Philippines quake turns seabed into shore
-
Stocks rally falters, oil rises as US-Iran talks postponed
-
S. Korean leader says he told Trump sanctions on North are 'ineffective'
-
Indonesia to capture last-known wild Bornean rhino for IVF
-
No vaccine, conflict, mistrust: Ebola's return to DR Congo
-
USA, Australia eye World Cup knockout rounds, Brazil in action
-
AI museum brings sights, sounds and smells of the rainforest
-
Iran to lodge complaint with FIFA over World Cup restrictions
-
'Old dog' Slipper out of retirement for Wallabies' Nations Championship campaign
-
New Zealand minister defends fishers after two orcas killed in net
-
Mexico into World Cup last 32, Canada celebrate historic win
-
Seoul record leads most Asian markets higher, crude extends losses
-
Co-hosts Mexico first team into World Cup knockout rounds
-
Burnham wins key UK poll, paving way for bid to challenge PM Starmer
-
Erasmus under 'no illusions' as tough Springboks season kicks off
-
'Pico' Lopes -- Cape Verde defender's journey from Ireland to World Cup
-
100 Colombian guerrillas disarm in deal with leftist government
-
'Pretty special': captains eye Super Rugby glory in clash of top seeds
-
Football 'ambassador' and fan favorite: a duck becomes a star in Mexico
-
Ivory Coast's Diomande living World Cup dream, dealing with tragedy
-
Slipper out of retirement for Wallabies' Nations Championship campaign
-
Australia seek 'respect' from US amid World Cup 'layup' row
-
New Zealand's Payne joins Paraguayan powerhouse after Instagram fame
-
Japan doctor-turned-author moots amputations to ease care crunch
-
Clark seizes four-stroke lead at darkness-halted US Open
-
Fossils challenge assumptions on how animals adapted to land
-
From private enterprise to property: Cuba's reforms unpacked
-
Canada romp to first World Cup win, Switzerland thump Bosnia
-
'Last ride': US says goodbye to Air Force One as Qatari jet awaits
-
Venezuela govt, opposition hold US-backed talks on democratic transition
-
Gabriel tells Brazil to turn the page against Haiti at World Cup
-
Horror injury overshadows Canada's first World Cup win
-
Cuba adopts historic package of free-market reforms
-
Swiss wunderkind Manzambi scores 'childhood dream' brace
-
US faces tough path to new Iran nuclear deal
-
Good US Open shots not good enough for 2-over Scheffler
-
Cuba unveils historic package of free-market reforms
-
Subs send Swiss to World Cup rout of Bosnia-Herzegovina
-
Stokes set for England return in New Zealand finale - reports
-
McIlroy pleased with reduced green speeds in US Open winds
-
Quarantine over for almost all hantavirus ship passengers, crew
-
US stocks resume upward climb as dollar advances again after Fed outlook
-
Ex-presidents and stars, but no Trump, turn out for Obama Library
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
D.Schneider--BTB